Compare NWPX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | CRVS |
|---|---|---|
| Founded | 1966 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.5M | 546.7M |
| IPO Year | 1995 | 2016 |
| Metric | NWPX | CRVS |
|---|---|---|
| Price | $67.41 | $25.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $60.00 | $28.00 |
| AVG Volume (30 Days) | 61.8K | ★ 7.1M |
| Earning Date | 02-25-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.50 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $519,991,000.00 | N/A |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | $18.40 | ★ N/A |
| Revenue Growth | ★ 7.64 | N/A |
| 52 Week Low | $36.97 | $2.54 |
| 52 Week High | $70.61 | $26.95 |
| Indicator | NWPX | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 91.48 |
| Support Level | $66.98 | $6.46 |
| Resistance Level | $70.61 | $7.18 |
| Average True Range (ATR) | 2.10 | 1.66 |
| MACD | 0.08 | 2.20 |
| Stochastic Oscillator | 65.15 | 91.63 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products. The Company is the manufacturer of engineered water transmission systems in North America and produces steel casing pipe, bar-wrapped concrete cylinder pipe, and pipeline system joints and fittings through its Engineered Steel Pressure Pipe segment. The Company provides solution-based products for a wide range of markets, including high-quality reinforced precast concrete products, lined precast sanitary sewer system components, water distribution and management equipment, including pump lift stations, wastewater pretreatment, and stormwater quality products through its Precast Infrastructure and Engineered Systems segment.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).